Patients with fatty liver disease and liver cancer are increasingly presenting with comorbidities including obesity and diabetes.
Associate Professor Martin Weltman heads the Nepean Hospital Department of Gastroenterology and Hepatology clinical and research programs in non-alcoholic steatohepatitis (NASH) - a fast progressing form of non-alcoholic fatty liver disease.
These patients are unable to benefit from or respond to many established treatments, including existing drug treatments and liver transplants.
The Department applies clinical research and innovative, collaborative, clinical practices to help these patients. Clinical research includes DNA and RNA analysis of patient blood and other samples to help inform better therapeutic treatments (pharmacogenetics).
Teaching and training the next generation of clinicians is also a key focus of the Department with senior medical trainees and students attached to the clinical and research programs.